GLP-1 Drugs May Trigger Muscle Loss In Cirrhosis Patients: Study

Drugs from the GLP-1 receptor agonist class, widely used for diabetes and weight loss, are now under scrutiny for their potential impact on muscle health in vulnerable patients. A new study published in a journal Gastroenterology and Hepatology suggests that these medications may be linked to muscle loss in individuals with liver cirrhosis, raising important clinical concerns. Losing weight can sometimes mean losing muscle too, which may lead to a condition called sarcopenia. This is well known in obesity medicine. That's why doctors usually recommend eating plenty of protein and doing strength training while losing weight with GLP-1 drugs. For people with liver cirrhosis, keeping muscle is even more important because sarcopenia increases the risk of the liver getting worse and can shorten life.

As per the study, patients with well-controlled cirrhosis and GLP-1 medications can be used carefully, but doctors need to pay close attention to protein intake, exercise, and signs of muscle loss.

What The Study Found

The study highlights that patients with liver cirrhosis who were treated with GLP-1 receptor agonists showed a greater tendency towards loss of skeletal muscle mass, a condition known as sarcopenia.

Cirrhosis itself already predisposes patients to muscle wasting due to altered metabolism and reduced protein synthesis. The addition of GLP-1 drugs, which promote weight loss and reduce appetite, may further accelerate this decline in muscle mass.

Also read: Beyond GLP-1: New 5-In-1 Compound More Effective Than Semaglutide For Diabetes And Weight Loss

Why Muscle Loss Matters In Cirrhosis

Muscle health is critical for patients with liver disease. Loss of muscle mass in cirrhosis is associated with:

• Reduced physical strength and mobility
• Higher risk of infections
• Poorer quality of life
• Increased risk of hospitalisation and mortality

Experts note that in such patients, weight loss is not always beneficial, especially if it involves loss of lean muscle rather than fat.

How GLP-1 Drugs May Contribute

GLP-1 receptor agonists work by reducing appetite, slowing gastric emptying and promoting weight loss. While these effects are beneficial in obesity and diabetes, they may have unintended consequences in cirrhosis patients. The study suggests possible mechanisms such as:

• Reduced calorie and protein intake
• Altered energy metabolism
• Increased breakdown of muscle tissue

Over time, this can contribute to progressive muscle depletion, particularly in already frail individuals.

Not All Weight Loss Is Healthy

GLP-1 drugs are often praised for their metabolic benefits, including improved blood sugar control and weight reduction. However, in patients with liver cirrhosis, these benefits may come with trade-offs. Doctors highlight that not all weight loss is healthy, and preserving muscle mass is crucial in chronic liver disease management.

What Patients Should Know

A study in the journal Clinical Gastroenterology and Hepatology, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show significant promise in managing liver cirrhosis, particularly by improving outcomes in patients with type 2 diabetes and MASLD/NAFLD. Studies indicate they reduce the risk of decompensation, cardiovascular events, mortality, and liver failure in compensated cirrhosis. But, experts advise that GLP-1 drugs should be used cautiously in patients with liver cirrhosis. Important considerations include:

• Monitoring body composition, not just weight
• Ensuring adequate protein intake
• Regular assessment of muscle strength and function
• Personalised treatment plans based on disease severity

Also read: Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment

Patients should not stop medication on their own but consult their doctor for guidance. The study raises an important clinical question: while GLP-1 drugs offer clear benefits in diabetes and obesity, they may pose risks for muscle health in patients with liver cirrhosis. This highlights the need for a balanced, individualised approach, where treatment goals go beyond weight loss to include preserving muscle and overall strength. For patients with liver disease, medical supervision is key to ensuring that treatment helps more than it harms.

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.